Access Delayed, Access Denied: Waiting for New Medicines in Canada
Author : Brett James Skinner
Publisher : The Fraser Institute
Page : 41 pages
File Size : 14,8 MB
Release : 2011
Category : Drug approval
ISBN :
Author : Brett James Skinner
Publisher : The Fraser Institute
Page : 41 pages
File Size : 14,8 MB
Release : 2011
Category : Drug approval
ISBN :
Author :
Publisher : The Fraser Institute
Page : 48 pages
File Size : 18,87 MB
Release : 2008
Category :
ISBN :
PR: the date at which the first public reimbursement of the new drug is recorded in the formularies of each federal, provincial, and territorial drug program. [...] For the purposes of this report, the global development time for new medicines is assumed to be a function of factors outside of Canada's control; therefore, the time associated with this segment is presented for completeness but is not the focus of the main policy discussion in this paper, nor is it part of the overall wait time for access to new medicines measured here. [...] In Canada, the time patients spend waiting for government approval of a new drug is measured from the date the drug manufacturer's application for approval is recorded or filed in the Central Registry (CR) of Health Canada's Therapeutic Products Director- ate (TPD) or Biologics and Genetics Therapies Directorate (BGTD) following the comple- tion of clinical testing. [...] Since 2004, the equivalent authority to approve pharmaceutical and biological medicines in the United States has fallen under the Department of Health and Human Services (HHS), with the Center for Drug Evaluation and Research (CDER), a part of the Food and Drugs Administration (FDA). [...] The delay in this segment is measured from the date at which Health Canada issues a NOC for a new drug to the date at which the first public reimbursement (PR) of the same drug is recorded in the formularies of each federal, provincial, and territorial drug program.
Author : G.Bruce Doern
Publisher : University of Toronto Press
Page : 281 pages
File Size : 25,40 MB
Release : 2012-06-20
Category : Political Science
ISBN : 1442694858
Biotechnology has become one of the most important issues in public policy and governance, altering the boundaries between the public and the private, the economic and the social, and further complicating the divide between what is scientifically possible and ethically preferred. Given the importance of biotechnology in shaping relations between the state, science, the economy, and the citizenry, a book that explores the Canadian biotechnology regime and its place in our democracy is timelier than ever. Three Bio-Realms provides the first integrated examination of the thirty-year story of the democratic governance of biotechnology in Canada. G. Bruce Doern and Michael J. Prince, two recognized specialists in governance innovation and social policy, look at particular ‘network-based’ factors that seek to promote and to regulate biotechnology inside the state as well as at broader levels. Unmatched by any other book in its historical scope and range, Three Bio-Realms is sure to be read for years to come.
Author : Brett J. Skinner
Publisher : The Fraser Institute
Page : 282 pages
File Size : 28,21 MB
Release : 2009
Category : Health services accessibility
ISBN : 0889752427
"This book is an edited version of the author's earlier published Ph.D. thesis, titled Barriers to Health Policy Liberalization in Canada: Institutions, Information, Interests and Incentives"--T.p. verso.
Author :
Publisher :
Page : 584 pages
File Size : 39,72 MB
Release : 2007
Category : Canada
ISBN :
Author : OECD
Publisher : OECD Publishing
Page : 164 pages
File Size : 38,94 MB
Release : 2010-09-14
Category :
ISBN : 9789264083240
This 2010 edition of OECD's periodic review of Canada's economy includes chapters covering policies to sustain the recovery, fiscal consolidation strategies, and health care reform.
Author : Sharon Batt
Publisher : UBC Press
Page : 397 pages
File Size : 23,17 MB
Release : 2017-06-15
Category : Social Science
ISBN : 0774833874
Over the past several decades, a gradual reduction in state funding has pressured patient groups into forming private-sector partnerships, raising an important ethical question: do these alliances ultimately lead to policies that are counter to the public interest? Health activist, scholar, and cancer survivor Sharon Batt examines the issue by investigating Canada’s breast cancer movement from 1990 to 2010. Health Advocacy, Inc. dissects the relationship between the companies that sell pharmaceuticals and the individuals who use them, drawing links between neoliberalism and corporate financing and the ensuing threat to the public health care system. Combining archival analysis, interviews with advocacy and industry representatives, and personal observation, Batt argues that the resulting power imbalance continues to challenge the groups’ ability to put patients’ interests ahead of those of the funders. A movement that once encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry. Batt’s thorough account of this shift defines the stakes of activism in public health today.
Author : United States. Congress. Senate. Committee on Finance. Subcommittee on International Trade
Publisher :
Page : 204 pages
File Size : 34,21 MB
Release : 2004
Category : Competition, International
ISBN :
Author :
Publisher : The Fraser Institute
Page : 39 pages
File Size : 27,71 MB
Release : 1979
Category : Health insurance
ISBN :
Author : Donald E. Abelson
Publisher : McGill-Queen's Press - MQUP
Page : 561 pages
File Size : 15,11 MB
Release : 2018-12-30
Category : Political Science
ISBN : 0773553851
It is often assumed that think tanks carry enormous weight with lawmakers and other key stakeholders. In Do Think Tanks Matter? Donald Abelson argues that the question of how think tanks have evolved and under what conditions they can and do have an impact continues to be ignored. Think tank directors often credit their institutes with influencing major policy debates and government legislation, and many journalists and scholars believe the explosion of think tanks since the latter part of the twentieth century is indicative of their growing importance in the policy-making process. Abelson goes beyond assumptions, highlighting both the visibility and relevance of public policy institutes in what has become a contentious and polarized political arena in the United States, and in Canada, where, despite recent growth in numbers, they enjoy less prominence than their US counterparts. By focusing on how think tanks engage in issue articulation, policy formation, and implementation, Abelson argues that they have helped to shape the political dialogue and the policy preferences and choices of decision-makers, but in different ways and at different stages of the policy cycle. This expanded and revised third edition includes additional institutional profiles of key think tanks, an updated chapter on presidents and think tanks, a new chapter on the efforts of a group of public policy institutes to shape the discourse around the possible construction of the controversial Keystone XL pipeline, and dozens of new graphs and tables that track the public visibility and perceived policy relevance or impact of top-tier think tanks.